Clinical Trials Browser

Completed × Prostatic Neoplasms × Bevacizumab × Clear all

NCT00942331 2023-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Phase 3 Completed

506 enrolled 13 charts

Carcinoma, Transitional Cell, Prostatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00942578 2018-10-11

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Phase 2 Completed

63 enrolled 23 charts

Prostatic Neoplasms

NCT01656304 2018-07-31

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

16 enrolled 12 charts

Prostatic Neoplasms

NCT00499694 2018-06-12

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Phase NA Completed

31 enrolled 8 charts

Prostatic Neoplasms

NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Phase 2 Completed

73 enrolled 16 charts

Neoplasms, Prostatic Neoplasms

NCT00658697 2017-05-25

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Phase 2 Completed

42 enrolled 10 charts

Prostatic Neoplasms

NCT00776594 2016-10-21

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Phase 2 Completed

102 enrolled 9 charts

Prostatic Neoplasms

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00110214 2014-05-09

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 3 Completed

1,050 enrolled 13 charts

Prostatic Neoplasms

NCT00016107 2013-06-05

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00027599 2013-02-11

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms